Incannex Healthcare (IXHL) Depreciation & Amortization (CF) (2023 - 2026)
Incannex Healthcare (IXHL) posted quarterly Depreciation & Amortization (CF) of $65000.0 for Q1 2026, up 1400.0% year-on-year from $4333.3 in Q1 2025, and up 10.17% on a QoQ basis from $59000.0 in Q4 2025.
Incannex Healthcare (IXHL) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Incannex Healthcare (IXHL) has reported Depreciation & Amortization (CF) for 4 consecutive years, with $65000.0 the latest figure, recorded in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 1400.0% year-over-year to $65000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $251000.0 (up 1.62% YoY) and the FY2025 annual result came in at $246000.0, up 138.83% from the prior year.
- Depreciation & Amortization (CF) improved to $65000.0 in Q1 2026 per IXHL's latest filing, from $59000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for IXHL reached as high as $126000.0 in Q4 2024 and fell as low as -$13000.0 in Q1 2023.
- A 4-year average of $45538.5 and a median of $61000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) slumped 129.41% — and 2026, when it soared 1400.0%.
- Year by year, Depreciation & Amortization (CF) stood at $12000.0 in 2023, then jumped by 950.0% to $126000.0 in 2024, then plunged by 53.17% to $59000.0 in 2025, then rose by 10.17% to $65000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $65000.0, $59000.0, and $66000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Incannex Healthcare | 3.63 Mn | 3.63 Mn | - | 65,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65,000.00 |
| Mar 31, 2026 | 65,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Dec 31, 2024 | 126,000.00 |
| Dec 31, 2024 | 126,000.00 |
| Sep 30, 2024 | 64,000.00 |
| Sep 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Mar 31, 2024 | 17,000.00 |
| Mar 31, 2024 | 17,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Dec 31, 2023 | 12,000.00 |